Clinical Trials Directory

Trials / Unknown

UnknownNCT04354519

The United Kingdom Multiple Sclerosis Register Covid-19 Substudy

The UK MS Regsiter COVID-19 Substudy

Status
Unknown
Phase
Study type
Observational
Enrollment
3,000 (estimated)
Sponsor
Swansea University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.

Detailed description

Study objectives 1. To identify the incidence of upper respiratory tract symptoms: fever, cough and breathing difficulties, other symptoms suggestive of COVID-19 infection, respiratory tract infections suggestive of COVID-19, and COVID-19 confirmed by laboratory testing among the UK MS population 2. To establish if some DMDs increase the risk of COVID-19 infection 3. To determine the incidence and effectiveness of self-isolation in the MS population. To examine the impact self-isolation has on mood, fatigue, and other routinely collected patient reported outcome measures from the MS Register. 4. To determine the clinical outcome of respiratory tract infections, including confirmed and suspected cases of COVID-19, in terms of symptoms, time to recovery, hospital admission, requirement for ventilation, and death. 5. To determine the longer-term impact of COVID-19 on MS, using routinely collected MS outcomes in the MS register, including impact on disability, relapses and changes in DMDs as assessed at 3 monthly intervals. 6. To determine where people are obtaining their health information during the COVID-19 outbreak. 7. To establish changes in DMDs prior to and as a result of symptoms related and unrelated to COVID-19

Conditions

Timeline

Start date
2020-03-14
Primary completion
2022-07-14
Completion
2022-07-14
First posted
2020-04-21
Last updated
2021-08-17

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04354519. Inclusion in this directory is not an endorsement.